Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on March 7, 2019. The filing discloses the execution of new employment agreements with the Company's President and Chief Executive Officer, Stephen L. Holcombe, and its Executive Vice President and Chief Financial Officer, Rudy C. Howard.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
- Executive Employment Agreements: New agreements were entered into on March 7, 2019, extending the terms of Mr. Holcombe and Mr. Howard through December 31, 2020.
- Stock Option Grants:
- Stephen L. Holcombe was granted an option to purchase 200,000 shares of Class A common stock based on 2018 performance.
- Rudy C. Howard was granted an option to purchase 125,000 shares of Class A common stock based on 2018 performance.
- Grant Timing: Both option grants are scheduled to take place on or within 30 days of March 7, 2019.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the standard disclosure that the employment agreements are qualified by reference to the full text of the contracts filed as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Review Exhibit 10.1 for the full terms of Stephen L. Holcombe's employment agreement and option grant conditions.
- Review Exhibit 10.2 for the full terms of Rudy C. Howard's employment agreement and option grant conditions.
- Verify the vesting schedule and exercise price for the 325,000 total shares of Class A common stock options granted.
- Confirm the specific termination provisions and severance arrangements detailed in the new contracts.